137EGP
- Active ingredient
- daunorubicin
- Strength
- 20 mg
- Form
- vial
- Manufacturer
- cipla ltd. - india > star international company
- Route
- injection
Uses
Anthracycline antineoplastic agent used in the treatment of acute myeloid leukemia, including therapy-related AML and AML with myelodysplasia-related changes.
Do not use if
History of serious hypersensitivity to daunorubicin or formulation components.
Side effects
May cause myelosuppression, hemorrhage, cardiotoxicity, hypersensitivity reactions, nausea, and tissue injury if extravasation occurs.
Warnings
Monitor for cardiotoxicity, severe myelosuppression, hemorrhage, and infusion-related complications.
How it works
Anthracycline topoisomerase inhibitor that interferes with DNA replication and promotes cancer cell death.
Storage
Store according to manufacturer recommendations in the original container.